Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
M200, Carboplatin, Paclitaxel, Bevacizumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab |
| Name | Type | Description |
|---|---|---|
| M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab | DRUG | Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin. |
Inclusion Criteria * Males and females of at least 18 years of age. * Stage IIIB with pleural effusion or Stage IV non-squamous NSCLC. * Measurable and/or evaluable disease according to RECIST. * No prior chemotherapy, biological therapy or immunotherapy for Stage IIIB/IV disease. Adjuvant therapy ...
Top 20 of 83 competitors